Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.32 |
| ▸ | PLAU | P00749 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13610891 | 0.80 | MEN1 (0.43) | MAPTKMT2ACYP3A4 | |
| SCHEMBL9910290 | 0.77 | CDK1 (0.39) | MAPTKMT2ACYP3A4PLAU | |
| SCHEMBL1791223 | 0.76 | EPAS1 (0.43) | MAPTKMT2A | |
| SCHEMBL2604029 | 0.71 | LMNA (0.34) | KMT2ACYP3A4 | |
| SCHEMBL15925253 | 0.70 | L3MBTL1 (0.46) | KMT2ATP53 | |
| SCHEMBL7190886 | 0.68 | CYP3A4 (0.60) | MAPTKMT2ASCN9ATP53CYP3A4 | |
| SCHEMBL12503575 | 0.67 | MGMT (0.35) | MAPTKMT2APLAU | |
| SCHEMBL7184434 | 0.65 | PDE7A (0.45) | MAPTKMT2ATP53CYP3A4 | |
| SCHEMBL13610940 | 0.65 | BRAF (0.59) | MAPTKMT2A | |
| SCHEMBL2603522 | 0.64 | FYN (0.43) | KMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013207-B1 | IMIDAZO[4,5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS CANCER THERAPEUTIC COMPOUNDS | CANCER REC TECH LTD (GB) | 2012-04-25 | — | — | EP | disclosed |